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Abstract
Background Among long-term care facility residents,
polypharmacy is common, and often appropriate, given the
need to treat multiple, complex, chronic conditions.
Polypharmacy has, however, been associated with increased
healthcare costs, adverse drug events, and drug interactions.
The current study evaluates the potential medication cost
savings of adding personalized pharmacogenetic informa-
tion to traditional medication management strategies.
Methods One hundred and twelve long-term care residents
completed pharmacogenetic testing for targeted variants in
the following genes: CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP3A4/CYP3A5, HTR2A, HTR2C, SLC6A4,
SLC6A2 COMT, OPRM1, SLCO1B1, VKORC1 and
MTHFR. Following reporting of the IDgenetix Polyphar-
macy test results, an internal medication management
assessment was performed by a licensed clinical pharma-
cist to identify potential opportunities for regimen opti-
mization through medication changes or discontinuations.
The medication cost differences before and after the
pharmacogenetic-guided review were assessed.
Results Medication review following pharmacogenetic
result reporting identified 54 patients (48.2%) with a total
of 132 drug change recommendations (45 reductions; 87
replacements) and an average of 2.4 proposed medication
changes (range 1–6) per patient. Medication cost savings
related to the identified reduction and replacement oppor-
tunities exceeded the cost of testing and are estimated to be
US$1300 (year 2016 cost) per patient annually assuming
full implementation.
Conclusion Compared with traditional medication review,
pharmacogenetic testing resulted in a 38% increase in the
number of patients with current medication change
opportunities and also offered valuable genetic information
that could be referenced to personalize future prescribing
decisions for all patients.
Key Points
When IDgenetix Polypharmacy test results were
added to a clinical pharmacist-guided medication
review for long-term care polypharmacy patients,
there was a 38% increase in patients identified with
medication change opportunities, and the modeled
drug cost savings exceeded testing costs within the
first year.
Pharmacogenetic testing informed clinical
prescribing recommendations for the majority of
patients with current medication change
recommendations, and provided personalized
information that could be referenced in the medical
record to inform future prescribing decisions.
1 Introduction
Polypharmacy is the concurrent use of multiple medica-
tions by a patient. Results of the 2004 National Nursing
Home Survey found the prevalence of polypharmacy (de-
fined as use of C9 medications) among nursing home
residents to be approximately 40% [1]. While the presence
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of multimorbidity for many long-term care facility patients
may necessitate polypharmacy, careful medication moni-
toring is essential as excessive polypharmacy or inclusion
of inappropriate medications may leave patients at risk for
drug interactions and adverse drug events (ADEs).
Polypharmacy is often associated with an increase in
unnecessary healthcare utilization due to drug interactions
and ADEs, and associated falls, medication non-adherence,
functional decline, and cognitive impairment, which result
in increases in healthcare costs [2]. Nguyen et al. reported
the incidence of adverse drug reactions among patients
taking nine or more medications to be 2.3 times higher than
among those patients taking fewer [3]; while a prospective
cohort study by Doan and colleagues found a 50% risk of
cytochrome enzyme-mediated drug–drug interactions
among older hospitalized adults taking between five and
nine medications and an increased risk of 100% among
patients taking[20 medications [4].
Several studies have looked at strategies to make
informed decisions to identify and reduce medications that
are involved in drug–drug or drug–disease interactions, are
potentially inappropriate in older adults, or may no longer
be useful. To identify medication targets for reduction,
such studies have utilized traditional resources such as
drug–drug interaction identification tools, Beers criteria of
potentially inappropriate medications, and drug indication
documentation [5–7]. Today’s medication therapy man-
agement utilizes a trial-and-error approach. A patient may
be prescribed multiple drugs, at various dosages, and over
extended periods of time before achieving the desired
therapeutic effect. New tools such as pharmacogenetic
(PGx) testing allow physicians to further personalize their
patient’s medication review. Utilizing the patient’s DNA,
PGx testing identifies how individuals may respond to
drugs based on their unique genetic profile. This can help
healthcare providers determine the right medication and the
right dosage for their patients in a timely manner.
The US Food and Drug Administration (FDA) maintains
a list of FDA-approved drugs and genes (currently 164
drug–gene pairs) with PGx information in their labeling,
and notes that PGx can play an important role in avoiding
adverse events, identifying responders and non-responders
to medications, and optimizing drug dosage [8]. The
Clinical Pharmacogenetics Implementation Consortium
(CPIC) curates a list of 199 drug–gene pairs, of which 70
have FDA PGx label information where genetic testing is
required, recommended, or considered ‘actionable’. Forty
of the drug–gene pairs are addressed in peer-reviewed
guidelines published by the expert members of CPIC to
support the ‘‘translation of genetic laboratory results into
actionable prescribing decisions for specific drugs.’’ [9].
Examples of drugs frequently prescribed in the long-
term care (LTC) population and having FDA label and/or
CPIC guidance include selective serotonin reuptake inhi-
bitors (SSRIs) (citalopram, escitalopram, sertraline,
paroxetine, fluvoxamine), codeine, clopidogrel, and war-
farin. The PGx guidance is based on cytochrome P450
(CYP450)-mediated metabolism (pharmacokinetics) for
these medications and the potential for genetic variants in
the CYP450 genes to alter the enzyme function and
increase or decrease drug metabolism. For example,
approximately 11% of Caucasian and 33% African
American patients have been reported to have a deletion of
both copies of their CYP2D6 gene, referred to as CYP2D6
*5 (CYP2D6 *5/*5 genotype) [10]. This results in a loss of
CYP2D6 function and a ‘poor metabolizer’ phenotype. The
CPIC guideline for ‘CYP2D6 and CYP2C19 Genotypes
and Dosing of Selective Serotonin Reuptake Inhibitors’
notes that CYP2D6 poor metabolizers should be prescribed
an alternative to paroxetine and fluvoxamine, or if use is
warranted, reduce dose by 50% (paroxetine) or 25–50%
(fluvoxamine) [11]. Similarly, CPIC guidelines recommend
that CYP2D6 poor metabolizers avoid use of codeine and
tramadol and exercise caution in using hydrocodone and
oxycodone since the metabolism of each of these anal-
gesics involves CYP2D6 [12].
The utility of integrating PGx information into pre-
scribing decisions has been assessed in a variety of settings.
Schildcrout et al. evaluated the frequency with which 56
medications known to be impacted by genetic variants
were prescribed among 52,942 medical home patients over
a 5-year period, and determined that 65% of the cohort
would be exposed to at least one PGx-influenced medica-
tion, and[10% would be exposed to at least four [13].
Several studies have evaluated the benefit of utilizing PGx
information prior to making prescribing decisions to avoid
ADEs and improve medication cost savings [13, 14], while
others have evaluated the use of PGx information to sup-
port medication changes following treatment failure and
ADEs, or to achieve reduction in polypharmacy [15, 16].
The aim of this study was to evaluate the medication
cost impact of pharmacist-guided, PGx-informed, regimen
review in patients receiving multiple medications in a long-
term care setting.
2 Methods
Samples were received for testing from patients residing in
one healthcare organization consisting of three LTC
facilities. Medication lists reflecting patient regimens (in-
cluding prescriptions, over-the-counter [OTC] medications,
and supplements) were submitted to the laboratory along
with a test order and the collected buccal swab. This
material and documentation provided the baseline infor-
mation for number of medications and dosages. All
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samples were processed in accordance with the Centers for
Medicare and Medicaid Services (CMS) regulations in a
College of American Pathologists (CAP)-accredited,
Clinical Laboratory Improvement Amendments (CLIA)-
certified laboratory (AltheaDx, CA, USA). Using cheek
swabs, buccal epithelial samples were collected and ship-
ped to the laboratory at room temperature, together with
test requisition forms and supporting documentation.
Genomic DNA was extracted (QIAGEN DSP DNA Midi
Kit, QIAgen, CA, USA) and quantified using a Nanodrop
8000 spectrophotometer (ThermoFisher Scientific, Wal-
tham, MA, USA). Genotyping was performed using the
TaqMan OpenArray platform (ThermoFisher, CA, USA)
and CYP2D6 copy number variation was performed using
TaqMan real-time PCR (ThermoFisher, CA, USA) to
identify targeted PGx variants in 15 genes: CYP1A2,
CYP2C9, CYP2C19, CYP2D6, CYP3A4/CYP3A5, HTR2A,
HTR2C, SLC6A4, SLC6A2 COMT, OPRM1, SLCO1B1,
VKORC1, and MTHFR. Variants tested in each of the
genes were found at approximately C1% in the US
population. Allele frequencies were monitored longitudi-
nally for quality control purposes.
Drug–gene and drug–drug interactions were identified
and characterized from an extensive review of FDA-ap-
proved package inserts, professional PGx guidelines (e.g.,
CPIC), and primary scientific literature. This information is
currently utilized in the proprietary IDgenetix Polyphar-
macy algorithm which was validated in accordance with
CLIA and Clinical and Laboratory Standards Institute
(CLSI) requirements. Results of genetic testing were pro-
cessed through the proprietary IDgenetix Polypharmacy
algorithm, evaluating the patient’s genetic results and CYP-
mediated drug interactions with concomitant medications,
herbal supplements or other dietary or environmental fac-
tors, to provide personalized result interpretations.
IDgenetix Polypharmacy results were provided back to the
referring physicians via reports which listed commonly used
medications grouped by indication and categorized as ‘use as
directed’ or ‘use with caution and/or increased monitoring’
based on patient results (Fig. 1).
Fig. 1 IDgenetix algorithm overview. The IDgenetix test uses a
proprietary algorithm to assess the appropriateness of a given
medication for a specific patient. (1) The process begins by the
physician providing a current medication list for the patient, termed
the ‘Preferred Drug List’. (2) The algorithm first identifies any
adverse drug–drug interactions through the ‘Concomitant Medication
Warning Filter’. (3) The algorithm then uses the genetic information
derived from the buccal swab to characterize any gene–drug
interactions using the ‘Single Gene Filter’. (4) Lastly, individual
gene–drug interactions are further cross-referenced against one
another to characterize any complex relationships among genes in
biochemical pathways in the ‘Multi-Gene Filter’. If a specific
medication does not have any drug–drug or drug–gene interactions
identified in any of the three filters, it is classified as ‘Use as Directed’
(see green arrows). If any one of the three algorithmic filters identifies
an issue with a specific drug, that compound is classified as ‘Use with
Caution’ (see orange arrows), and the appropriate warnings are
provided. The ‘Use as Directed’ and ‘Use with Caution’ classifica-
tions are then used by the physician for making an informed decision
on medication therapy management
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Following reporting to the referring physician, an
IDgenetix internal medication management assessment
was performed by a licensed Doctor of Pharmacy
(Pharm.D.) to identify potential opportunities for regimen
optimization through medication changes or discontinua-
tions implied by the PGx analysis. Other more traditional
considerations influential to the proposed improvements
included drug–drug and drug–disease state interaction
evaluation and pill burden reduction through the use of
combination products (regimen consolidation). To facili-
tate data analysis, the suggested changes were categorized
according to their principle motivation as follows: ‘genet-
ics: pharmacokinetic (PK) gene’, where a CYP gene vari-
ant predicts increased or decreased drug metabolism;
‘genetics: pharmacodynamic (PD) gene’, where a non-CYP
gene variant impacts drug response; ‘drug–drug interac-
tions’; ‘drug–disease state interactions’; and ‘regimen
consolidation’, where an alternate medication with addi-
tional therapeutic benefit or a combination medication
could reduce pill burden.
The predicted medication costs associated with the
Pharm.D.-identified regimen modification opportunities
were modeled. For each medication, the current dosage
was determined from review of medication orders that
accompanied the sample submission documentation. The
average wholesale price (AWP) corresponding to the
appropriate formulation was determined on a per-month
basis, using per-pill pricing derived from UpToDate/Lex-
icomp [17]. A 16.4% ingredient cost and US$3.73 dispense
fee was then applied to the initial AWP, per State of
Florida guidelines in ‘Medicaid Covered Outpatient Drug
Reimbursement Information’ for quarter ending December
2014 [18]. The net change in medication costs were cal-
culated for the patients with recommended changes by
adding the savings from drug reductions to the cost dif-
ference (increased or decreased) resulting from drug
replacements accounting for the cost of testing for all
patients (i.e. those with and without recommended chan-
ges). The overall cost savings were calculated over 1-, 2-,
and 2.3-year (average length of study for nursing home
patients [19]) timelines and cost differences were also
assessed according to therapeutic drug class.
3 Results
Samples were received for testing from 116 patients and
results were reported for 112 patients (two patients had
their test order cancelled by the referring physician, one
patient sample had insufficient DNA, and one patient
sample failed due to the assay). Among the 112 reported
patients, 64 (57%) were female, 48 (43%) were male, and
the average age was 74.2 years (range 34–100). Review of
detailed medication orders for each patient revealed
patients to be taking an average of 19 (range 6–40) phar-
macologically active substances combining prescription
and OTC medications and herbal/vitamin supplements.
3.1 Patients with Change Recommendations
After Pharm.D. review, 132 drug change recommendations
(45 reductions; 87 replacements) were identified for 54
patients (48.2% of tested population), with an average of
2.4 medication changes (range 1–6) per patient. The bases
for the recommended therapeutic modifications among the
54 patients are displayed in Table 1 and Fig. 2. A patient
may have had one or more identified reasons for their
medication changes. For instance, for 12 patients, change
recommendations were noted for three reasons, genetics:
PK gene (metabolizer status) related, genetics: PD gene
related, and drug–drug interactions. PGx results were a
factor in one or more modification recommendations for
94.4% (51/54) of patients. Individually, altered metabolizer
phenotype (PK), as determined by CYP gene variant status,
impacted current medications for 79.6% (43/54) of
patients, and PD gene variants were implicated for 61.1%
(33/54).
As displayed in Table 1, 15 of the 54 patients had
medication change reasons that were exclusively genetic
(PK, PD, or both). This represents a 38.4% (15/39) increase
in patients identified with medication change opportunities
as compared with traditional evaluations relying solely on
drug–drug or drug–disease state interactions, which would
have identified only 39 patients in the current analysis.
The overall cost savings within a 12-month period for
the 112 patients in this study (including all drug classes
evaluated) was calculated to be US$145,664 (year 2016
cost). This translates to an estimated savings of approxi-
mately US$1300 per patient on an annualized basis. Given
that the average length of stay for a nursing home resident
is 2.3 years [19], this translates to a cumulative savings of
approximately US$3000 per patient over their entire length
of stay.
When predicted cost savings were evaluated by thera-
peutic treatment class, the greatest savings among drug
reductions were seen for gastrointestinal and psychotropic
drugs. Among drug replacements, psychotropic drugs had
the greatest cost savings, followed by cardiovascular. Taken
together, gastrointestinal, psychotropic, and cardiovascular
drug reductions and replacements accounted for over
US$150,000 in annualized savings and accounted for 87%of
the patients evaluated. The predominance of these thera-
peutic areas among the proposed interventions reflects the
relatively larger contributions of thesemedical disciplines to
the current PGx knowledge base. At present, practitioners
utilizing these therapeutic classes could gain most from
932 E. A. Sugarman et al.
adopting this approach. However, PGx therapeutic applica-
bility can only broaden as the range and scope of validated
clinically relevant PGx associations expands.
3.2 Patients without Change Recommendations
When the same criteria for potential change recommen-
dations (genetics: PK, genetics: PD, drug–drug interaction,
regimen consolidation, and drug–disease interaction) were
applied to all 112 patients, no change recommendations
were made for 58. Among the 58 patients for whom no
changes to their current regimen were identified, the
average age was 76.6 years and the average number of
current medications was 16.8 (range 6–35). We assessed
the frequency of select genetic variants that could impact
clinician decision making if future medication changes
were to be considered. These findings are displayed in
Table 2.
Table 1 Reasons for clinical pharmacist medication change recommendations. Drug classes evaluated included gastrointestinal, psychotropic,
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Fig. 2 Reasons for medication
change recommendations
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4 Discussion
Previous studies of pharmacist or physician medication
management review have focused on drug–drug interac-
tions or potentially inappropriate medications [5, 6]. In the
current study, we add another valuable, personalized,
patient variable to the assessment: PGx. Patient medica-
tions were identified as candidates for reduction or
replacement based on PGx findings, drug–drug interac-
tions, drug–disease interactions or opportunities for regi-
men consolidation.
Additional insight from genetic analysis can inform
selection of medications for reduction or replacement, and,
in combination with drug interaction information, identify
patients for whom the impact of combined drug–drug
interaction and genetics (phenoconversion) poses a greater
risk than would be recognized were either considered in
isolation. Genetic analysis can guide both medication
prescribing and deprescribing as well as enhance drug–
drug interaction evaluation by informing the impact of
metabolic inducers and inhibitors. To illustrate, consider
the example case of a 79-year-old male whose extensive
regimen included amiodarone, paroxetine, spironolactone,
tamsulosin, warfarin, lorazepam, tramadol, meloxicam,
zolpidem, insulin, digoxin, alendronate, bumetanide, and
levothyroxine. Genetic analysis revealed variant results
predictive of CYP2D6 poor metabolizer (PM) and
CYP2C9 intermediate metabolizer (IM) phenotypes. As
several of the patient’s medications are CYP2D6 (parox-
etine, tamsulosin, tramadol) and CYP2C9 (warfarin,
meloxicam) substrates, knowledge of the patient’s altered
metabolizer status provides valuable insight for safer
medication selection. For paroxetine, CYP2D6 PM status
increases the likelihood of adversity due to greater sys-
temic exposure, while its antiplatelet and osteopenic effects
threaten to exacerbate comorbidities. The combination of
CYP2D6 PM paired with CYP3A4 inhibition from
amiodarone poses risks for tramadol (decreased efficacy,
increased adversity) and tamsulosin (increased risk of
hypotension, orthostasis, and syncope). Both paroxetine
and tramadol are included on the FDA Pharmacogenomic
Biomarkers in Drug Labeling list for CYP2D6 poor
metabolizer status and have CPIC guidelines noting cau-
tion for use in 2D6 PMs. Similarly, warfarin appears on the
FDA Biomarker list and in CPIC guidelines for CYP2C9
reduced function. This patient’s CYP2C9 IM result in
combination with amiodarone CYP2C9 inhibition leads to
increased systemic exposure and sensitivity to minor
changes in dosage, suggesting that a switch to a direct-
acting oral anticoagulant (apixaban, dabigatran, edoxaban
or rivaroxaban), dosed appropriately for renal function,
might be beneficial. Medication recommendations included
replacement of tramadol with hydromorphone, replacement
of paroxetine with mirtazapine, and reduction of zolpidem
leading to an estimated annualized savings of US$934.
Previous studies employing medication management
review followed by implementation of recommended
drug reductions have demonstrated substantial health and
cost benefits. Garfinkel and colleagues implemented
discontinuation of 332 different drugs among 119 study
patients in a geriatric nursing ward without significant
adverse effects. In comparison with a 71-patient control
group, the study patients had significantly lower referral
rates to acute care facilities, 1-year mortality rates, and
drug costs [20].
Our study added a Pharm.D. review of PGx results to the
traditional medication review resources. The inclusion of
PGx criteria resulted in 38% more patients being identified
with reduction/replacement opportunities than would have
been identified on the basis of drug–drug, drug–disease or
regimen consolidation opportunities alone. The goal was to
use these factors to model optimization of patient medi-
cation regimens. As such, rather than focus solely on
opportunities to eliminate medications, we sought to both
Table 2 Frequency of select metabolic and genetic alterations among patients without current regimen change recommendations




dosage adjustment or caution
CYP2C19-altered metabolism (PM or UM) 19 32.8 Tricyclic antidepressants, citalopram,
escitalopram, clopidogrel
CYP2D6 altered metabolism (UM or IM) 2 3.5 Codeine, hydrocodone
CYP2C9 (reduced function) plus VKORC1
(c.-1639G[A A/G or A/A)
10 17.2 Warfarin
SLCO1B1 (c.521T[C C/T or C/C) 15 25.9 Simvastatin
OPRM1 (c.118 A[G A/G or G/G) 12 20.7 Morphine, hydrocodone, other opioids
HTR2A (c.998G[A G/G or A/A) 28 48.3 SSRIs
IM intermediate metabolizer, PM poor metabolizer, SSRIs selective serotonin reuptake inhibitors, UM ultrarapid metabolizer
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eliminate potentially ineffective medications and to also
replace medications with unfavorable profiles with those
that could offer improved treatment options.
All 112 patients referred for testing were taking six or
more medications at the time of testing. Of the 112
patients, 107 (95.5%) were taking C10 medications (in-
cluding prescription and OTC medications). It is unclear
whether this high frequency reflects patient selection for
PGx testing from these nursing home facilities or is
reflective of the larger resident population. Previous studies
of polypharmacy (defined as nine or more medications)
among nursing home residents have reported rates of 39.7
and 46.3% [1, 6], while an earlier, unpublished analysis of
polypharmacy among[37,000 samples referred to our lab
for clinical PGx testing identified 44% of patients having
more than nine medications. Given the multiple morbidi-
ties and clinical complexity of most nursing home resi-
dents, use of multiple medications is not unexpected. With
research supporting a strong association between
polypharmacy and increased risk for adverse drug events,
drug interactions, medication non-adherence, and falls,
medication management strategies aimed at reducing
unnecessary or genetically incompatible medications are
expected to benefit patient health while reducing costs
[2, 6, 21].
While our analysis focused on medication cost changes
related to proposed regimen modifications in the 54
patients deemed upon Pharm.D. review to potentially
benefit from reductions or replacements to their current
regimen, PGx results were obtained for all 112 patients.
PGx information in the patient medical record is of clinical
value in informing future prescribing decisions for all
patients. Among the patients without current change rec-
ommendations, for example, 22% carry a c.118 A[G
variant in the OPRM1 gene that has been associated with
higher sensitivity to pain, higher opioid dosage requirement
to achieve analgesic effect, and unchanged or lower risk for
opioid-related side effects [22]. As nursing home clinicians
adjust patient medications in response to changing needs
for pain control, knowledge of a patient’s OPRM1
c.118A[G status can help inform medication selection and
dosage decisions.
Our analysis modeled medication cost savings related
to the Pharm.D.-recommended drug reductions and
replacements in a polypharmacy nursing home population
and estimated cost savings of US$1300, US$2600, and
US$3000 per patient at 1, 2, and 2.3 years, respectively.
Previous studies of pharmacist [5] or physician [6]
interventions on medical management of a long-term care
population have reported 80 and 86% acceptance of
interventions by the primary attending physician, while
Brixner et al., evaluating a clinical decision support tool
in a[65-year-old cohort, found providers followed 46%
of test recommendations [16]. If we apply a conservative
70% acceptance rate to our recommendations, the
resulting annual medication cost savings of US$910.40
exceeds the cost of PGx testing in the first year. As studies
of medication review and reduction in polypharmacy
nursing home patients have previously demonstrated
[6, 20, 23], we would expect implementation of our
medical management strategy to conservatively yield not
only medication cost savings but also potential additional
healthcare cost savings resulting from reductions in
adverse drug events, hospitalizations, falls, and medica-
tion administration costs. A similar cost analysis was
performed by Saldivar et al. [15] using the IDgenetix
Polypharmacy test demonstrating annual savings of
US$621 per patient. The primary drug class that con-
tributed the most cost savings in that study was psy-
chotropic drugs. In contrast, the greatest savings in our
study were mostly attributed to gastrointestinal medica-
tions. Additionally, our study resulted in greater cost
savings (US$1300 vs US$621 on an annual basis), indi-
cating that the IDgenetix Polypharmacy test is capable
of generating a range of savings from a variety of dif-
ferent drug classes.
While numerous studies have evaluated methods and
benefits of medication management review and depre-
scribing in long-term care facilities, here we illustrate the
potential impact of adding personalized PGx information to
the medication review process. Among patients with rec-
ommended drug reductions or replacements, PGx results
were a contributing factor in one or more recommended
changes in 94%, and resulted in a 38% increase in the
number of patients identified with medication change rec-
ommendations than would be recognized by traditional
review criteria. These are promising results, yet limitations
present in this study should be addressed in future efforts.
Our analysis was based on independent review of regimen
information by a single clinical pharmacist, and medication
change recommendations were not communicated and
implemented, therefore acceptance rate and follow-up
monitoring for efficacy and side-effect profiles could not be
established. Our cost analysis was a simple pre- versus
post-PGx and projected cost savings based on a subset of
patients tested and was not compared with a control group.
In future studies, a more formal economic analysis can be
done to account for adverse drug reactions and the asso-
ciated medical costs along with projected medication sav-
ings from PGx testing, utilizing a control and experimental
group.
Future studies evaluating the integration of PGx test
results into medication management review (including
physician alerts through an electronic medical record sys-
tem), implementation of recommendations, and resulting
healthcare and cost benefits will help assess the great
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potential for continually improving patient care with a truly
personalized medicine approach.
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